ThePromiseofLowDoseNaltrexoneTherapy

Naltrexoneisanopiateantagonistdrugdevelopedinthe1970sandapprovedbytheFDAin1984asasafeandeffectivetreatmentforopiateanddrugabuse.Whenusedatmuchlowerdosesinanoff-labelprotocolreferredtoaslowdosenaltrexone(LDN),thedrughasbeenshowntohaltdiseaseprogressioninCrohn'sdiseaseandcertaincancers,includingpancreaticcancer,andtoreducesymptomsinmultiplesclerosisandautism.WhileongoingclinicaltrialsareevaluatingtheuseofLDNintreatingfibromyalgiaandHIV/AIDS,ithasbeenshowntoimprovenumerousautoimmuneandneurodegenerativeconditions,includingParkinson'sdiseaseandamyotrophiclateralsclerosis(ALS).Groundedinavailableclinicalandscientificresearch,thisbookdescribesthehistoryofnaltrexone,includingitspotentialtherapeuticuses,itseffectsontheimmunesystem,anditspharmacologicalproperties.AimingtoacquaintreaderswiththepotentialtherapeuticbenefitsofLDN,thebookalsoincludespracticalchaptersforthoseinterestedinitsuse,focusingonsuchtopicsashowthedrugisadministered,informationonfillersandcompoundingpharmacies,listsofdoctorswhoprescribeLDN,andavailablepatientresources.ItalsofeaturesinterviewswithLDNpatientsandseveralofthecountry'stopLDNresearchers,whodescribetheimportanceofLDNintermsofitsabilitytoproviderelieffrompain,haltdiseaseprogression,andfacilitatethebody'sabilitytoheal.Finally,theworkincludesausefulglossaryandanappendixlistingimportantclinicaltrialscompletedtodate,completewithresearchercontactinformationandasummaryofthetrialoutcomes.